Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duolac7S
- Development stage
- Unknown
- Lead developer
- Cell Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Duolac7S is a multi-strain probiotic mixture (live biotherapeutic) developed by Cell Biotech Co., Ltd. It contains seven viable bacterial strains, including *Bifidobacterium brevis*, *Bifidobacterium lactis*, *Streptococcus thermophilus*, *Lactobacillus rhamnosus*, *Lactobacillus plantarum*, and *Lactobacillus acidophilus*. The product is designed to modulate the gut microbiota and colonic microflora, primarily for the treatment of diarrhea-dominant irritable bowel syndrome (D-IBS). It aims to alleviate symptoms such as abdominal pain, bloating, and altered stool frequency. Duolac7S has been evaluated in randomized, double-blind, placebo-controlled clinical trials, both as a standalone therapy and in combination with the Korean herbal medicine Gwakhyangjeonggisan (GJS). Additionally, it has been studied for its ability to aid in the recovery of intestinal flora following bowel preparation for colonoscopy.
- Brand names
- Duolac7SDuolac-7SDuolac 7S
- Other names
- Duolac 7SDuolac7SDuolac-7S
Beyond the preview
Go deeper on Duolac7S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duolac7S.